

Lao PDR Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

| | | | | | |
|---|------------|------------|------------|------------|--------------------|
| 1. Country: Lao PDR | | | | | |
| 2. Grant number: 1720-LAO-18b-X / 17-LAO-08k-Y / | | | | | |
| 3. Date of Decision Letter: 05 May 2017 | | | | | |
| 4. Date of the Partnership Framework Agreement: 7 June 2013 | | | | | |
| 5. Programme title: New Vaccine Support (NVS), Measles-Rubella SD routine | | | | | |
| 6. Vaccine type: Measles-Rubella | | | | | |
| 7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED | | | | | |
| 8. Programme duration¹: 2017 - 2020 | | | | | |
| 9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable) | | | | | |
| | 2017 | 2018 | 2019 | 2020 | Total ² |
| Programme Budget (US\$) | US\$77,000 | US\$59,500 | US\$50,000 | US\$33,500 | US\$220,000 |
| 10. Vaccine introduction grant (in US\$): 149,500. Payable up to six months before vaccine introduction. | | | | | |
| 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ³ | | | | | |
| Type of supplies to be purchased with Gavi funds in each year | 2017 | 2018 | | | |
| Number of Measles-Rubella vaccines doses | 122,200 | 94,100 | | | |
| Annual Amounts (US\$) | US\$77,000 | US\$59,500 | | | |
| 12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF. | | | | | |
| 13. Self-procurement: Not applicable | | | | | |

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

14. Co-financing obligations: Reference code: 1720-LAO-18b-X-C

According to the co-financing policy, the Country falls within the group Accelerated transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

| Type of supplies to be purchased with Country funds in each year | 2017 | 2018 | 2019 | 2020 |
|--|------------|------------|-------------|-------------|
| Number of vaccine doses | 99,100 | 122,900 | 170,500 | 210,800 |
| Number of AD syringes | 74,000 | 83,000 | | |
| Number of re-constitution syringes | 10,900 | 13600 | | |
| Number of safety boxes | 950 | 1075 | | |
| Value of vaccine doses (US\$) | US\$60,418 | 74968 | | |
| Total co-financing payments (US\$) (including freight) | US\$66,500 | US\$82,000 | US\$114,000 | US\$140,500 |

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable

| Reports and other information | Due dates |
|---|-------------------------------|
| To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | May |
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Secretariat |

17. Financial clarifications: Country shall provide the following clarifications to Gavi*:

Not applicable

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: not applicable

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

05 May 2017

Lao PDR Support for Injection Safety Devices

This Decision Letter sets out the Programme Terms of a Programme.

| | | | | | |
|--|--------|-------------|-------------|-------|--------------------|
| 1. Country: Lao PDR | | | | | |
| 1. Grant number: 17-LAO-32a-X / 18-LAO-32a-X / 19-LAO-32a-X / 20-LAO-32a-X | | | | | |
| 2. Date of Decision Letter: 05 May 2017 | | | | | |
| 3. Date of the Partnership Framework Agreement: 7 June 2013 | | | | | |
| 4. Programme title: Immunisation supplies ¹ | | | | | |
| 5. Programme duration²: 2017 - 2020 | | | | | |
| 6. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable) | | | | | |
| | 2017 | 2018 | 2019 | 2020 | Total ³ |
| Programme Budget (US\$) | 56,000 | 4,000 | 3,500 | 2,000 | 65,500 |
| 7. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴ | | | | | |
| TOTAL immunisation supplies to be purchased with Gavi funds in each year | | 2017 | 2018 | | |
| Number of AD syringes | | 1,076,200 | 63,500 | | |
| Number of re-constitution syringes | | 13,500 | 10,400 | | |
| Number of safety boxes | | 12,075 | 825 | | |
| Annual Amounts for immunisation supplies for all Gavi vaccines (US\$) | | 56,000 | 4,000 | | |
| Immunisation supplies to be purchased with Gavi funds in each year, <u>by type of support</u> | | | | | |
| New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose(s) per vial LIQUID, Routine | | 2017 | 2018 | | |
| Number of AD syringes | | 322,500 | | | |
| Number of re-constitution syringes | | | | | |
| Number of safety boxes | | 3,575 | | | |

¹ This does not include vaccines.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the amount that Gavi has approved.

| | | |
|---|---------|--------|
| Annual Amounts for immunisation supplies for Vaccine (US\$) | 16,500 | |
| New Vaccine Support (NVS), DTP-HepB-Hib, 1 dose(s) per vial, LIQUID | 2017 | 2018 |
| Number of AD syringes | 506,200 | |
| Number of re-constitution syringes | | |
| Number of safety boxes | 5,600 | |
| Annual Amounts for immunisation supplies for Vaccine (US\$) | 26,000 | |
| New Vaccine Support (NVS), Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID,Routine | 2017 | 2018 |
| Number of AD syringes | 156,200 | |
| Number of re-constitution syringes | | |
| Number of safety boxes | 1,725 | |
| Annual Amounts for immunisation supplies for Vaccine (US\$) | 8,000 | |
| New Vaccine Support (NVS), Measles Rubella, 10 dose(s) per vial, LYOPHILISED,SD routine | 2017 | 2018 |
| Number of AD syringes | 91,300 | 63,500 |
| Number of re-constitution syringes | 13,500 | 10,400 |
| Number of safety boxes | 1,175 | 825 |
| Annual Amounts for immunisation supplies for Vaccine (US\$) | 5,500 | 4,000 |
| 8. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF. | | |
| 9. Self-procurement: Not applicable | | |
| 10. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter. | | |

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

05 May 2017